Healing the heart naturally: The role of bioactive phytocompounds in cardiovascular therapeutics.

BACKGROUND

Cardiovascular diseases remain the leading cause of global mortality, with a consistently rising burden in low- and middle-income countries. Limitations and adverse effects of conventional therapies have increased interest in plant-derived therapeutic alternatives.

PURPOSE: This review aims to evaluate the therapeutic potential of bioactive phytocompounds from medicinal plants in preventing the development of CVD by promoting cardiovascular health.

STUDY

DESIGN

This proposed study uses a narrative literature review design to examine experimental/clinical findings on plant-based cardioprotective substances.

METHODS

We analysed published preclinical and clinical research on the major active phytochemicals, including curcumin, resveratrol, ginsenosides, berberine, quercetin, and catechins. We discussed their molecular mechanisms, pharmacological actions, and emerging nanotechnology-based delivery systems in detail. We also analysed their impact on gut microbiota-derived metabolites, including TMAO, short-chain fatty acids, and bile acids.

RESULTS

Bioactive phytocompounds exerted a pronounced cardioprotective effect by attenuating oxidative stress and inflammation, improving endothelial dysfunction, and restoring lipid metabolism and mitochondrial integrity. These bioactive compounds enhanced nitric oxide bioavailability and effectively regulated calcium signalling, NF-κB, and MAPK pathways, while also modulating microbiota-related metabolites. Nanotechnology-based formulations further improved biocompatibility and tissue specificity. Hypertension, atherosclerosis, myocardial ischemia, and heart failure had strong clinical efficacy and validated safe use.

CONCLUSION

Bioactive phytocompounds offer a holistic and sustainable approach to managing cardiovascular disease. However, standardization, well-designed clinical trials, and regulatory harmonization are still required to facilitate the integration of these therapies into mainstream cardiovascular medicine.